Opinion

Video

PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors

Author(s):

Virginia G. Kaklamani, MD, DScHeather McArthur, MD, MPH

The expert panel examines the subgroup data from the postMONARCH study, focusing on patients with ESR1 and PIK3CA mutations, and emphasizes the important role of CDK4/6 inhibitors in the treatment of these specific patient populations with HR+/HER2- metastatic breast cancer.

  1. PostMONARCH Subgroup data in ESR1 and PIK3CA
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
The OncFive: Top Oncology Articles for the Week of 8/25
August 31st 2024

The OncFive: Top Oncology Articles for the Week of 8/25

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

State of the Science Summit - Breast Cancer: Chaired by Christos Vaklavas, MD
August 29th 2024

State of the Science Summit - Breast Cancer: Chaired by Christos Vaklavas, MD

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
August 22nd 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

Shipra Gandhi, MD
August 26th 2024

CDK4/6 Inhibitors, ADCs, and PI3K Inhibitors Individualize HR+ Breast Cancer Management

Bruce G. Haffty, MD, MS
August 25th 2024

NSABP B-51 Data Highlight Evolving Role of Radiation in Early-Stage Breast Cancer